Key result
Ex vivo modifications of mesenchymal stem cells targeting proinflammatory signaling pathways hold potential to improve donor-cell survival and cardioprotective efficacy in ischemic heart disease.
Understanding and modifying stem cell signaling pathways offers a promising strategy to overcome the limitations of low donor-cell survival and transient functional recovery in cell-based therapies for cardiac ischemia.
Cardiovascular disease remains a leading cause of mortality in developed nations, despite continued advancement in modern therapy. Progenitor and stem cell-based therapy is a novel treatment for cardiovascular disease, and modest benefits in cardiac recovery have been achieved in small clinical trials. This therapeutic modality remains challenged by limitations of low donor-cell survival rates, transient recovery of cardiac function, and the technical difficulty of applying directed cell therapy. Understanding the signaling mechanisms involved in the stem cell response to ischemia has revealed opportunities to modify directly aspects of these pathways to improve their cardioprotective abilities. This review highlights general considerations of stem cell therapy for cardiac disease, reviews the major proinflammatory signaling pathways of mesenchymal stem cells, and reviews ex vivo modifications of stem cells based on these pathways.
No takes yet. Share an insight, caveat, or question.
Herrmann et al. (2009) conducted a review in Cardiac Ischemia. Stem cell therapy was evaluated. Ex vivo modifications of mesenchymal stem cells targeting proinflammatory signaling pathways hold potential to improve donor-cell survival and cardioprotective efficacy in ischemic heart disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: